Atheroma Progression in Obese Early-stage Diabetic Japanese XXXX in Response to Glycemic Control: Sub-analysis from the DIANA Study.

@entity1 @entity6 @entity28 @entity731 @entity1144 @entity412 @entity47506 @entity209 @entity453 @entity413
UNASSIGNED: Aim: @entity6 is accompanied by @entity1144 , which produces various @entity209 . While metabolic factors have been considered to promote the development of @entity453 in the early-stage of @entity6 , it remains unknown whether the presence of @entity28 in early-stage diabetics affects the natural history of @entity453 . We herein investigated the characteristics of the disease substrate in @entity28 early-stage diabetics.Methods: The DIANA ( @entity6 and diffuse coronary NArrowing) study was a serial evaluation of angiographic disease progression in early-stage diabetics with @entity453 . A total of 252 study subjects were stratified into @entity28 (n=168) and @entity28 groups (n=84). @entity28 in Japanese subjects was defined as a body mass index >= 25 kg/m(2) according to the statement about Japanese @entity28 from the Japan Society for the Study of @entity28 . Coronary atherosclerotic changes were evaluated by a quantitative computed analysis. The total lesion length ( @entity47506 =total length of all @entity731 ) was compared between the groups.Results: The @entity28 @entity1 were younger (p=0.0002) and had higher levels of fasting (p=0.002) and postprandial insulin (p=0.01), and higher @entity412 levels (p=0.02). On serial angiographic evaluations, @entity28 @entity1 had greater disease progression, reflected by a larger percent change in the @entity47506 (24.7  13.7 vs. 7.4  10.0%, p=0.04). However, the improvement of abnormal @entity413 tolerance was associated with a slowing of disease progression in both @entity28 (-0.9  10.7 vs.    15.0  11.2%, p=0.04) and @entity28 (   4.2  22.8 vs.    55.5  26.5%, p=0.005) @entity1 .Conclusions: Obese @entity1 with early-stage @entity6 exhibit profound disease progression. Glycemic control attenuated the progression of their @entity453 . Our findings indicate progressive but modifiable disease in @entity28 early-stage diabetics under optimal glycemic management.
